Disease · MONDO_0021042

glioma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. glioma. Diseases, record MONDO_0021042. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021042

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: glioma; Open Targets
Open Targets ID: MONDO_0021042; Open Targets
Other names: glial neoplasm, glial tumor, glial tumour, neoplasm of neuroglia, neoplasm of the neuroglia, neuroglial neoplasm, neuroglial tumor, neuroglial tumour, tumor of neuroglia, tumor of the neuroglia, tumour of neuroglia, tumour of the neuroglia; Open Targets
MeSH: D005910; MeSH
NCI Thesaurus: C3059; NCI Thesaurus
Orphanet: ORPHA:182067; Orphanet
Highest stage of its drugs: Approval, for 11 of its 186 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Drugs186

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TEMOZOLOMIDE	CHEMBL810	Small molecule	Approval	EMA Human Drugs	55	48	48	Drugs and targets
VORASIDENIB	CHEMBL4279047	Small molecule	Approval	ClinicalTrials.gov	8	7	7	Drugs and targets
CARMUSTINE	CHEMBL513	Small molecule	Approval	DailyMed	4	2	2	Drugs and targets
DABRAFENIB	CHEMBL2028663	Small molecule	Approval	EMA Human Drugs	3	2	2	Drugs and targets
DORDAVIPRONE	CHEMBL4297310	Small molecule	Approval	ClinicalTrials.gov	3	2	2	Drugs and targets
TRAMETINIB	CHEMBL2103875	Small molecule	Approval	EMA Human Drugs	3	2	2	Drugs and targets
AMINOLEVULINIC ACID HYDROCHLORIDE	CHEMBL1200582	Small molecule	Approval	DailyMed and EMA Human Drugs	3	1	1	Drugs and targets
PROCARBAZINE HYDROCHLORIDE	CHEMBL1200410	Small molecule	Approval	PMDA	2	1	1	Drugs and targets
ALANINE	CHEMBL279597	Small molecule	Approval	TTD	1	0	0	Drugs and targets
IOPAMIDOL	CHEMBL1200932	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets

1 to 10 of 186

See all 186 drugs

Targets279

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TUBA1A	Tubulin	9	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	9	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	9	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	9	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	9	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	9	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 2	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	9	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 2	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	9	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 2	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	9	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 2	https://conductscience.org/library/genes/7280	Drugs and targets
TUBB2B	Tubulin	9	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Phase 2	https://conductscience.org/library/genes/347733	Drugs and targets

1 to 10 of 279

See all 279 targets

Trials187

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 7 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04164901	Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)	Phase 3	331	2023-11-24	Grade 2 Glioma, Residual Glioma, Recurrent Glioma	VORASIDENIB	Its record names the disease	ClinicalTrials.gov
NCT02986178	Lerapolturev in Recurrent Malignant Glioma	Phase 2	121	2025-07-11	Malignant Glioma	LOMUSTINE	Its record names the disease	ClinicalTrials.gov
NCT00100802	Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas	Phase 2	118	2017-01-13	Anaplastic Astrocytoma, Central Nervous System Neoplasm, Glioblastoma, Gliosarcoma, Spinal Cord Neoplasm	LOMUSTINE, TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT01303835	Low Dose Naltrexone for Glioma Patients	Phase 2	110	2015-06-26	Malignant Glioma	NALTREXONE	Its record names the disease	ClinicalTrials.gov
NCT03684811	A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation	Phase 1/2	93	2023-01-25	Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma, Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations	AZACITIDINE, CISPLATIN, GEMCITABINE, NIVOLUMAB, OLUTASIDENIB	Its record names the disease	ClinicalTrials.gov
NCT00271609	Bevacizumab for Recurrent Malignant Glioma	Phase 2	88	2012-06-08	Recurrent High-Grade Gliomas, Malignant Gliomas	BEVACIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT05267106	Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations	Phase 2	83	2025-12-30	Glioblastoma, Adult-type Diffuse Gliomas	PEMIGATINIB	Its record names the disease	ClinicalTrials.gov
NCT03914742	BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations	Phase 1/2	67	2024-12-16	IDH1 Mutation, IDH2 Mutation, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma	PAMIPARIB, TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT01402063	PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation	Phase 2	63	2015-06-11	Glioblastoma Multiforme	PACLITAXEL POLIGLUMEX, TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT03463265	Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma	Phase 2	62	2023-11-07	High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma	BEVACIZUMAB, LOMUSTINE, MARIZOMIB, SIROLIMUS, TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 187

See all 187 trials

Comparisons in its trials19

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Vorasidenib vs Matching Placebo: Objective Response (OR) as Assessed by the Blinded Independent Review Committee (BIRC)	18 of 168	4 of 163	331	NCT04164901	Trial comparisons
Vorasidenib vs Matching Placebo: Complete Response (CR) and Partial Response (PR) by BIRC	2 of 168	0 of 163	331	NCT04164901	Trial comparisons
Vorasidenib vs Matching Placebo: deaths from any cause	0 of 167	0 of 163	330	NCT04164901	Trial comparisons
Vorasidenib vs Matching Placebo: serious adverse events	11 of 167	8 of 163	330	NCT04164901	Trial comparisons
Lerapolturev vs Lerapolturev + Lomustine: Number of Participants With Objective Radiographic Response	5 of 93	2 of 27	120	NCT02986178	Trial comparisons
Lerapolturev vs Lerapolturev + Lomustine: Safety of Lerapolturev	17 of 94	8 of 26	120	NCT02986178	Trial comparisons
Naltrexone vs Placebo: serious adverse events	12 of 54	17 of 56	110	NCT01303835	Trial comparisons
Anaplastic Glioma (AG) vs Glioblastoma Multiforme (GBM): Number of Participants With Adverse Events	32 of 32	51 of 56	88	NCT00271609	Trial comparisons
Anaplastic Glioma (AG) vs Glioblastoma Multiforme (GBM): serious adverse events	11 of 32	24 of 56	88	NCT00271609	Trial comparisons
Recurrent Glioblastoma vs Recurrent Non-glioblastoma CNS Tumors: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)	73 of 74	9 of 9	83	NCT05267106	Trial comparisons

1 to 10 of 19

See all 19 comparisons in its trials

Papers from its trials131

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40241281	RESULT	1	PubMed
38724526	RESULT	1	PubMed
37861218	RESULT	1	PubMed
37759444	RESULT	1	PubMed
37272516	RESULT	1	PubMed
36691030	RESULT	1	PubMed
36689692	RESULT	1	PubMed
36362482	RESULT	1	PubMed
36090479	RESULT	1	PubMed
35780235	RESULT	1	PubMed

1 to 10 of 131

See all 131 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0021042

GET https://conductscience.org/api/diseases/v1/MONDO_0021042/drugs?page=2

API reference For AI assistants